Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 390 participants.

Also called NCT06528262

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 390 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06528262
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06528262. Randomized; quadruple masking; primary purpose treatment. Start 2025-04-03 (actual); primary completion 2027-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation
Acronym
ENAVO-AF
Intervention (Drug)
Enavogliflozin
Intervention (Drug)
Placebo
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct06528262
Content hash
0211b73375eb3a5c1baa821db36fc7f9c7825656cfeed8537a535a5b6f2ece65